Daclizumab

I moved Daclizumab from phase 2 to phase 3 based on this press release. The drug is still in a phase 2b trial for MS, but they are going ahead with planning for the phase 3 without waiting for the conclusion of the phase 2. I don’t know if this is because Facet Biotech is really confident in daclizumab, or if they are trying to impress investors or get some kind of milestone payment from Biogen.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: